5-氨基苯并呋喃-2-酮 | 83528-03-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 5-氨基苯并呋喃-2-酮
• 中文别名: 5-氨基-1-苯并呋喃-2(3H)-酮
• 英文名称: 3-aminocoumaranone
• 英文别名: 5-Aminobenzofuran-2(3H)-one；5-amino-3H-1-benzofuran-2-one
• CAS: 83528-03-4
• 化学式: C₈H₇NO₂
• mdl: MFCD18071596
• 分子量: 149.149
• InChiKey: XZXLYGAUEAPJET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2932209090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (14S)-14β-formylepitriptolid 、 5-氨基苯并呋喃-2-酮 在 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以50%的产率得到(14S)-14β-(2-oxo-2,3-dihydrobenzofuran-5-ylamino)methylepitriptolide
  参考文献：
  名称：

  Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide

  摘要：

  Two series of novel C14 heterocycle substituted epi-triptolide derivatives as potential anticancer agents were synthesized and tested for their cytotoxicity against SKOV-3 and PC-3 tumor cell lines. The introduction of C14 beta-aryl heterocycle aminomethyl substituent to the leading compound was found to be an effective modification method to retain the potent anticancer activity. Meanwhile, the series of epitriptolide derivatives (21-40) with C14 alpha-hydroxyl group, still retained the natural product's cytotoxicity. This is apparently challenges the classical structure activity relationship of triptolide that considers the C14 beta-hydroxyl group to be essential for its anticancer activity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.11.044
• 作为产物：
  描述：

  3-叠氮苯基乙酸 在 三氟甲磺酸 作用下， 以 四氢呋喃 为溶剂， 以36%的产率得到5-氨基苯并呋喃-2-酮
  参考文献：
  名称：

  Intramolecular cyclization of arylnitrenium ions. Formation of carbon-carbon bonds and of lactones

  摘要：

  DOI：

  10.1021/jo00145a056

文献信息

• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS<br/>[FR] 2, 6-DIAMINO-PYRIMIDIN- B-YL-CARBOXAMIDES SERVANT D'INHIBITEURS DE Syk KINASES ET DE JANUS KINASES
  申请人：PORTOLA PHARM INC

  公开号：WO2009145856A1

  公开（公告）日：2009-12-03

  The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma.

  本发明涉及式I-II的化合物及其药学上可接受的互变异构体、盐或立体异构体，这些化合物是syk和/或JAK激酶的抑制剂。本发明还涉及用于制备这类化合物的中间体，制备这种化合物，含有这种化合物的药物组合物，抑制syk和/或JAK激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗由syk和/或JAK激酶活性至少部分介导的多种疾病的方法，如心血管疾病、炎症性疾病、自身免疫疾病和细胞增殖障碍、血栓形成、过敏、哮喘、类风湿关节炎、白血病或非霍奇金淋巴瘤。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• Substituted quinazolines and analogs and the use thereof
  申请人：Euro-Celtique S.A.

  公开号：US20030033089A1

  公开（公告）日：2003-02-13

  The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

  本发明涉及新型的喹唑啉和杂环化合物，它们是AMPA受体的拮抗剂或正向调节剂，并用于治疗、预防或改善与中风、全局和局部缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗或改善包括阿尔茨海默病、肌萎缩性侧索硬化、亨廷顿病、帕金森病和唐氏综合症在内的神经退行性疾病，治疗、预防或改善兴奋性氨基酸过度刺激的不良后果，治疗、预防或改善焦虑、精神病、惊厥、慢性疼痛、青光眼、视网膜炎、尿失禁、肌肉痉挛和诱导麻醉，以及治疗或改善兴奋性氨基酸缺乏的不良后果，如精神分裂症、肌阵挛、阿尔茨海默病和营养不良和神经发育不良，并作为认知和学习增强剂。
• Inhibitors of protein kinases
  申请人：Bauer Shawn M.

  公开号：US20090318407A1

  公开（公告）日：2009-12-24

  The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及式I-II化合物及其药学上可接受的互变异构体、盐或立体异构体，其是SYK和/或JAK激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体，该化合物的制备，含有该化合物的制药组合物，抑制SYK和/或JAK激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗由SYK和/或JAK激酶活性至少部分介导的多种疾病，如不良血栓和非霍奇金淋巴瘤的方法。